|
Antares Pharma understands antagonism towards needles. The company develops needle-free systems for administering injectable drugs. Its Medi-Jector Vision system, for instance, injects a thin, high-pressure stream of liquid, eliminating the need for a needle. The Vision system is used primarily for the delivery of insulin and of human growth hormones; it is available over-the-counter and by prescription in the US and is also sold overseas. In addition to its needle-free systems, the company develops other drug delivery platforms, including topical gels, orally-administered disintegrating tablets, and mini-needle injection systems.
|
| | | Contact Information | |
Address: |
250 Phillips Blvd., Ste. 290
Ewing, NJ 08618
| | Phone: | 609-359-3020 | | Fax: | 609-359-3015 |
|
| Financial
Highlights | | Fiscal Year End: | December | | Revenue (2008): | 5.70 M | | Revenue Growth (1 yr): | (-28.00%) | | Employees (2008): | 24 | | Employee Growth (1 yr): | (-27.30%) |
|
|
Key People
| | • |
Chairman:
Leonard S. Jacob
| | • |
President, CEO, and Director:
Paul K. Wotton
| | • |
SVP, CFO, and Secretary:
Robert F. (Bob) Apple
|
|
|
